Ambroxol in New and Early DLB, A Phase IIa Multicentre Randomized Controlled Double Blind Clinical Trial
Status:
Recruiting
Trial end date:
2023-12-01
Target enrollment:
Participant gender:
Summary
This is a confirmatory investigational medicinal product (IMP) study to investigate the
effects on cognition, functional decline and on neuropsychiatric symptoms of the
Glucocerebrosidase (GCase) enhancing chaperone ambroxol in participants diagnosed with
prodromal and early dementia with Lewybodies (DLB).